GFA
ANIK icon

Gallagher Fiduciary Advisors’s Anika Therapeutics ANIK Stock Holding History

Gallagher Fiduciary Advisors’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-13,347
Closed -$141K – 308
2025
Q2 		$141K Buy
13,347
+2,361
+21% +$29.8K 0.01% 311
2025
Q1 		$165K Buy
+10,986
New +$183K 0.01% 294
2024
Q4 		– Sell
-8,809
Closed -$218K – 299
2024
Q3 		$218K Buy
+8,809
New +$228K 0.04% 245

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TI
Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Gallagher Fiduciary Advisors's ANIK Position: Q3 2025 in Review

Gallagher Fiduciary Advisors sold out of Anika Therapeutics (ANIK) in Q3 2025, closing a stake of 13,347 shares — an estimated $141K sold.

Gallagher Fiduciary Advisors first reported a position in ANIK in Q3 2024 and held it in 3 quarters. The position peaked at $218K in Q3 2024. 117 funds tracked by Wall St. Rank hold ANIK as of Q3 2025.

  • Gallagher Fiduciary Advisors reported no remaining Anika Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Gallagher Fiduciary Advisors sold 13,347 Anika Therapeutics shares in Q3 2025, an estimated $141K.
  • Gallagher Fiduciary Advisors first reported a position in Anika Therapeutics in Q3 2024 and held it in 3 quarters.
  • Gallagher Fiduciary Advisors's Anika Therapeutics position peaked at $218K in Q3 2024.
  • 117 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2025.

Based on Gallagher Fiduciary Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.